Otsuka Precision Health

What Otsuka Precision Health does

Otsuka Precision Health (OPH) is a wholly-owned digital health subsidiary of Otsuka Pharmaceutical Co., Ltd., headquartered at 508 Carnegie Center Drive in Princeton, NJ, founded in 2024 with 51-100 employees. The company operates a 'high-tech, high-touch' model that combines an AI/ML/NLP-powered data platform with human patient experience services to deliver personalized health engagement across the patient journey, positioning itself around the concept of 'health experience' rather than episodic patient experience.

OPH's product portfolio spans three branded digital products and a B2B platform. Rejoyn is an FDA-authorized prescription digital therapeutic for adjunctive treatment of Major Depressive Disorder in adults on antidepressants, distributed through healthcare provider prescriptions with optional nurse support lines. Elevmi is a consumer mobile application that uses empathetic AI dialogue trained on caregiver insights to support family caregivers of Alzheimer's patients. Mindful Mamas, acquired in 2025, is a maternal mental wellness platform with over 2,000 five-star ratings offering guided meditations, mood tracking, and sleep support. The B2B layer consists of an AI-powered digital navigation hub (implemented via partner The Rx Assistant) that pharmaceutical manufacturers license for 24/7 omnichannel patient and provider engagement, addressing medication access and adherence.

The business model blends four revenue streams: subscription/recurring revenue from prescription digital therapeutics (Rejoyn) and consumer mobile apps (Elevmi, Mindful Mamas); B2B licensing/royalty revenue from the navigation hub technology sold to pharmaceutical manufacturers; and professional services revenue from a patient experience services team that helps individuals overcome treatment barriers via in-person and technology-enabled channels. Go-to-market is hybrid: direct healthcare provider prescription for Rejoyn, self-serve app store distribution for consumer apps, and enterprise sales to pharma manufacturers for B2B offerings. The company is HIPAA, GDPR, and CCPA compliant, holds FDA authorization for its lead product, and is led by an executive team drawn from Amgen, Google, DaVita, Celgene/BMS, and Otsuka.

Name

Otsuka Precision Health

Legal name

Otsuka Precision Health, Inc.

Website

https://otsuka-oph.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

51–100 employees

Short description

Otsuka Precision Health is a Princeton-based digital health subsidiary of Otsuka Pharmaceutical that builds AI-powered personalized health products, including the FDA-authorized prescription digital therapeutic Rejoyn (MDD), the Elevmi caregiver support app for Alzheimer's families, and the acquired Mindful Mamas maternal wellness platform.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Health Services (8000)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

akta.pro secondary industries

Sleep, Stress & Mood Support (HLAIADAG), Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices) (CRACAQAL)

Keywords

• Digital therapeutics
• Prescription digital health
• Patient engagement platform
• AI health platform
• Caregiver support app

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Prescription Digital Therapeutics: Revenue from FDA-authorized prescription digital therapeutics like Rejoyn, delivered as mobile applications for treatment of conditions such as major depressive disorder as adjunct to clinician-managed care
2. Mobile Health Applications: Consumer-facing mobile applications like Elevmi for caregiver support and Mindful Mamas for maternal mental health, distributed through app stores
3. B2B Patient Engagement Solutions: AI-powered digital navigation hub technology sold to pharmaceutical manufacturers to improve patient and provider engagement, medication access and adherence
4. Patient Experience Services: Specialized patient experience services helping individuals overcome barriers to treatment through in-person and technology-enabled channels

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Otsuka Precision Health develops and sells a portfolio of digital health products and services built on an AI/ML/NLP-powered data platform. Its flagship consumer offerings are Rejoyn, an FDA-authorized prescription digital therapeutic for major depressive disorder, plus AI-driven mobile apps Elevmi (Alzheimer's caregiver support) and Mindful Mamas (maternal wellness). On the B2B side, it licenses an AI-powered omnichannel digital navigation hub to pharmaceutical manufacturers and provides patient experience services to improve adherence and outcomes.

Product overview

Otsuka Precision Health offers a portfolio of digital health products and services organized around a 'high-tech, high-touch' approach to personalizing healthcare. The core Data & Technology Platform unifies data sources and leverages AI/ML/NLP to connect people to the right products at the right time. The digital product portfolio includes Rejoyn (an FDA-authorized prescription digital therapeutic for MDD), Elevmi (an AI-powered mobile app for Alzheimer's caregivers), and Mindful Mamas (an acquired maternal wellness platform). Patient Experience Services provides technology-enabled support for disease management. The company also implements third-party platforms like The Rx Assistant for medication access and adherence.

Differentiator

Problem solved

Functional benefit

Brands

• Rejoyn: FDA-authorized prescription digital therapeutic for the adjunctive treatment of Major Depressive Disorder (MDD) symptoms. Delivers clinically proven exercises via mobile app to improve brain communication for emotional processing.
• Elevmi
• Mindful Mamas

Products and services

• Rejoyn Rejoyn is an FDA-authorized prescription digital therapeutic that delivers clinically proven neurobehavioral exercises via a mobile app to improve communication between the thinking and feeling parts of the brain, serving as adjunctive treatment for adults (22+) with Major Depressive Disorder on antidepressants.
• Elevmi Elevmi is an AI-powered mobile app that helps familial caregivers of people with Alzheimer's disease by instantly connecting them to practical education, resources, and tailored tools for caregiving and self-care, featuring empathetic AI dialogue trained on real caregiver insights.
• Mindful Mamas Mindful Mamas is a digital platform built by mothers for mothers that supports mental and emotional well-being across every stage of motherhood through guided meditations, mood tracking, and sleep support tools.
• B2B Patient Engagement Digital Navigation Hub (Rx Assistant) An AI-powered digital navigation hub providing 24/7 omnichannel support via voice, SMS, and chat, licensed to pharmaceutical manufacturers to improve patient and provider engagement, medication access, and adherence.
• Patient Experience Services Patient Experience Services is a specialized OPH team that uses in-person and technology-enabled channels to help individuals overcome barriers to treatment and achieve better, sustained disease management and quality of life through tailored engagement.

Quantifiable outcome

• A majority of studies reported positive association between higher continuity of care and at least one health outcome
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• The Rx AssistantcoreTechnology or Integration · 3 February 2026Otsuka Precision Health has implemented The Rx Assistant's AI-powered digital navigation hub technology for pharmaceutical manufacturers to improve patient and provider engagement through 24/7 omnichannel support via voice, SMS, and chat, addressing medication access and adherence challenges.
• Health RhythmsminorStrategic or Co-development PartnerHealth Rhythms is listed as a partner/investor in the Partners & Investors section of Otsuka Precision Health's About page, indicating a collaborative relationship in the digital health ecosystem.
• Oui TherapeuticsminorStrategic or Co-development PartnerOui Therapeutics appears as a partner logo on the OPH About page, suggesting a collaborative partnership in the health technology space.
• CuriominorStrategic or Co-development PartnerCurio is featured as a partner in OPH's Partners & Investors section, indicating a collaborative relationship in the digital health ecosystem.
• AmalgamminorStrategic or Co-development PartnerAmalgam is listed as a partner on OPH's About page, representing a collaborative partnership in health technology.
• Click TherapeuticsminorStrategic or Co-development PartnerClick Therapeutics is featured as a partner in OPH's Partners & Investors section, indicating collaboration in prescription digital therapeutics.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Happify Health: Happify Health combines AI-driven digital therapeutics and consumer wellness for mental health, overlapping with OPH's Elevmi (caregiver support) and Mindful Mamas (maternal wellness) product categories. Similar hybrid Rx/consumer model.
• Headspace Health: Headspace Health (the combined Headspace and Ginger entity) offers mental wellness apps and virtual mental health care, comparable to OPH's consumer wellness portfolio (Mindful Mamas, Elevmi) and adjacent to Rejoyn's mental health focus.
• Big Health: Big Health develops digital therapeutics for mental health conditions including insomnia (Sleepio) and anxiety (Daylight), directly competing with OPH's Rejoyn in the FDA-cleared mental health DTx category.
• Akili Interactive: Akili Interactive is a digital therapeutics company with FDA-authorized products targeting cognitive and mental health conditions. Comparable in business model (FDA-cleared software-based therapeutics) and target customer overlap (patients seeking adjunctive digital treatment).
• Woebot Health: Woebot Health builds AI-powered mental health chatbots and digital therapeutic tools, directly comparable to OPH's empathetic AI dialogue capabilities in Elevmi and the broader AI-driven mental health engagement platform.
• Click Therapeutics: Click Therapeutics develops prescription digital therapeutics across multiple indications and is both an OPH partner and a direct competitor in the FDA-authorized DTx space. Their overlapping focus on clinically validated, prescription-grade digital therapeutics makes them the closest comparable peer.
• Pear Therapeutics: Pear Therapeutics was the pioneer in FDA-authorized prescription digital therapeutics across multiple indications including mental health, and remains the benchmark case study for the DTx business model despite its 2023 bankruptcy. Highly relevant for understanding reimbursement and commercial dynamics OPH must navigate.

Emerging players

• Cerebral: Cerebral is a telehealth platform focused on mental health treatment including depression and anxiety, overlapping with OPH's MDD focus (Rejoyn) and adjacent in business model (digital-first mental health treatment for adults).
• Lyra Health: Lyra Health is a mental health benefits platform providing therapy, coaching, and digital tools through employer partnerships. Comparable to OPH's employer/B2B engagement model and overlapping target customer (adults with mental health needs) though delivered via live care rather than digital therapeutics.

Broad incumbents

• Omada Health: Omada Health is an established virtual care company offering digital therapeutics for chronic conditions (diabetes, hypertension, behavioral health). Comparable in the broader digital therapeutics category and in employer/B2B channel strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/oph-inc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Otsuka Precision Health